Immuneering Corporation reports clinical oncology developments centered on Deep Cyclic Inhibitors, a category of cancer medicines the company is developing for durability, tolerability and combinability. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK being studied across MAPK pathway-driven tumors, including pancreatic cancer.
Recurring updates include survival and safety data from atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, molecular and circulating tumor DNA analyses tied to MAPK resistance mechanisms, and presentations at oncology meetings such as ASCO and AACR. Company news also covers financial results, R&D spending, pipeline strategy, regulatory-readiness activities and healthcare-conference presentations.
Immuneering Corporation (Nasdaq: IMRX) announced its inclusion in the Nasdaq Biotechnology Index (NBI), effective December 20, 2021. This addition, less than five months post-initial public offering, aims to enhance visibility within the investment community. CEO Ben Zeskind highlighted the promising performance of the company’s lead candidate, IMM-1-104, demonstrating tumor growth inhibition across multiple animal models. The firm focuses on developing treatments for solid tumors driven by oncogenic mutations, supported by a pipeline encompassing six other oncology and two neuroscience programs.
Immuneering Corporation (Nasdaq: IMRX) announced its participation in several December investor conferences to discuss its oncology pipeline and business strategy. Key events include the Piper Sandler Global Healthcare Conference and Evercore ISI HealthCONx Conference, where executives will engage in investor meetings and fireside chats. The company focuses on developing therapies that target oncogenic signaling pathways, notably with its lead product candidate IMM-1-104, aimed at advanced solid tumors. Immuneering emphasizes its proprietary platform driven by translational bioinformatics.
Immuneering Corporation (Nasdaq: IMRX) announced its participation in the upcoming Jefferies 2021 London Healthcare Conference, scheduled for November 16-19, 2021. Company executives, including CEO Ben Zeskind, will present virtually on November 18 at 08:00 GMT (03:00 AM ET). The presentation will highlight their innovative pipeline of oncology drug candidates, particularly focusing on their lead product, IMM-1-104, a selective dual-MEK inhibitor for advanced solid tumors. A live webcast will be available from November 18 at 3:00 AM ET, with on-demand access until November 19 at 12:00 PM ET.
Immuneering Corporation (Nasdaq: IMRX) successfully completed its upsized IPO, raising $129.4 million in gross proceeds, providing funding into 2024. The company expects to file an IND application for IMM-1-104, a dual-MEK inhibitor targeting RAS mutant tumors, in Q1 2022. Financial results for Q3 2021 show a cash position of $159.6 million, research expenses of $6.2 million, and a net loss of $8.5 million or $0.47 per share. The company is focused on advancing its oncology pipeline and presented promising preclinical data for IMM-1-104.
Immuneering Corporation (Nasdaq: IMRX) has revealed promising preclinical data for its lead product candidate, IMM-1-104, presented at the recent AACR-NCI-EORTC conference. The dual-MEK inhibitor showed extensive antitumor activity across various RAS and RAF mutant tumor models, including KRAS mutations. Notably, IMM-1-104 in combination with sotorasib demonstrated superior tumor regressions. The company plans to file an Investigational New Drug application with the FDA in Q1 2022, aiming to progress into human clinical trials in H1 2022.
Immuneering (Nasdaq: IMRX) announced promising preclinical data for its lead product candidate, IMM-1-104, a selective dual-MEK inhibitor targeting RAS mutant tumors. The data demonstrates broad antitumor activity and tolerability, to be presented at the AACR-NCI-EORTC conference from October 7-10, 2021. The company plans to submit an IND application to the FDA in Q1 2022. A Key Opinion Leader event is scheduled for October 12, 2021, to discuss these findings further.
Immuneering Corporation (Nasdaq: IMRX) has been included in the Russell 2000® Index as of September 20, 2021. This addition highlights the company’s successful Initial Public Offering and its dedication to oncology drug development targeting the RAS/MAPK pathway. The Russell 2000® Index includes around 2,000 small-cap companies and is widely utilized as a benchmark for investment strategies, with $9 trillion in assets linked to it. Immuneering’s focus on advancing therapies for cancer and neurological diseases is part of its robust pipeline aimed at improving patient outcomes.
Immuneering Corporation (Nasdaq: IMRX) announced the completion of an upsized initial public offering, raising $129.4 million in gross proceeds to support its pipeline. The company expects to file an IND for IMM-1-104 in Q1 2022, targeting RAS mutant tumors. As of June 30, 2021, cash and equivalents stood at $50.2 million. R&D expenses rose to $7.0 million for Q2 2021, while net loss increased to $7.9 million or $1.61 per share, compared to the previous year. Management changes were made to strengthen leadership and expand the board.
Immuneering Corporation (Nasdaq: IMRX) announced its participation in two virtual investor conferences in September 2021. Management, including CEO Ben Zeskind and CFO Biren Amin, will discuss the company’s pipeline and business strategy. The first event is Morgan Stanley’s Global Healthcare Conference, with a presentation on September 14 at 4:15 p.m. ET. The second event is Oppenheimer's Life Sciences & Med Tech Summit, with a presentation on September 21 at 4:35 p.m. ET. Both presentations will be webcast and archived for 30 days on the company’s Investor Relations website.
Immuneering Corporation (Nasdaq: IMRX) has successfully completed its upsized initial public offering, closing on 8,625,000 shares of Class A common stock at $15.00 per share, yielding approximately $129.4 million in gross proceeds. The offering included a full exercise of the underwriters' overallotment option for 1,125,000 shares. Shares commenced trading on the Nasdaq on July 30, 2021. The funds raised are aimed at enhancing Immuneering's ongoing pipeline, which focuses on innovative oncology and neuroscience treatments.